
Lantheus Holdings, Inc. – NASDAQ:LNTH
Lantheus Holdings stock price today
Lantheus Holdings stock price monthly change
Lantheus Holdings stock price quarterly change
Lantheus Holdings stock price yearly change
Lantheus Holdings key metrics
Market Cap | 6.21B |
Enterprise value | 6.08B |
P/E | 210.61 |
EV/Sales | 6.50 |
EV/EBITDA | 74.33 |
Price/Sales | 6.32 |
Price/Book | 13.22 |
PEG ratio | 1.51 |
EPS | 6.72 |
Revenue | 1.36B |
EBITDA | 559.92M |
Income | 460.53M |
Revenue Q/Q | 23.00% |
Revenue Y/Y | 32.97% |
Profit margin | 3% |
Oper. margin | 3.87% |
Gross margin | 62.21% |
EBIT margin | 3.87% |
EBITDA margin | 41% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeLantheus Holdings stock price history
Lantheus Holdings stock forecast
Lantheus Holdings financial statements
$159
Potential upside: 187.41%
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 321.7M | 94.13M | 29.26% |
---|---|---|---|
Sep 2023 | 319.94M | 131.95M | 41.24% |
Dec 2023 | 353.99M | 103.38M | 29.2% |
Mar 2024 | 369.97M | 131.06M | 35.43% |
Jun 2023 | 1337720000 | 785.07M | 58.69% |
---|---|---|---|
Sep 2023 | 1521610000 | 822.85M | 54.08% |
Dec 2023 | 1651149000 | 835.25M | 50.59% |
Mar 2024 | 1831334000 | 885.79M | 48.37% |
Jun 2023 | -32.26M | -20.69M | -4.05M |
---|---|---|---|
Sep 2023 | 116.73M | 83.21M | 108K |
Dec 2023 | 112.28M | -12.06M | -450K |
Mar 2024 | 127.23M | -106.52M | -16.84M |
Lantheus Holdings alternative data
Sep 2023 | 698 |
---|---|
Oct 2023 | 698 |
Nov 2023 | 698 |
Dec 2023 | 698 |
Jan 2024 | 698 |
Feb 2024 | 698 |
Apr 2024 | 834 |
May 2024 | 834 |
Jun 2024 | 834 |
Jul 2024 | 834 |
Lantheus Holdings other data
Period | Buy | Sel |
---|---|---|
Dec 2023 | 0 | 10341 |
Jan 2024 | 0 | 341 |
Feb 2024 | 0 | 341 |
Mar 2024 | 0 | 158706 |
Apr 2024 | 0 | 341 |
May 2024 | 0 | 35266 |
Jun 2024 | 0 | 341 |
Jul 2024 | 0 | 14667 |
Aug 2024 | 0 | 31481 |
Nov 2024 | 0 | 23487 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Option | MARKISON BRIAN A director, officer.. | Common Stock | 16,666 | $6 | $99,996 | ||
Option | MARKISON BRIAN A director, officer.. | Common Stock | 16,102 | $12.42 | $199,987 | ||
Option | MARKISON BRIAN A director, officer.. | Stock Option (right to buy) | 32,768 | $9.21 | $301,793 | ||
Sale | MARSHALL ROBERT J. JR. officer: CFO and .. | Common Stock | 10,000 | $81.2 | $812,000 | ||
Sale | BLANCHFIELD PAUL officer: President | Common Stock | 2,000 | $79.65 | $159,300 | ||
Sale | HEINO MARY ANNE director | Common Stock | 7,487 | $86.32 | $646,278 | ||
Sale | HEINO MARY ANNE director | Common Stock | 400 | $86.93 | $34,772 | ||
Sale | HEINO MARY ANNE director | Common Stock | 2,900 | $88.78 | $257,462 | ||
Sale | HEINO MARY ANNE director | Common Stock | 700 | $89.58 | $62,706 | ||
Sale | THRALL JAMES H director | Common Stock | 1,000 | $98.52 | $98,520 |
Quarter | Transcript |
---|---|
Q1 2024 2 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 22 Feb 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 3 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 3 Aug 2023 | Q2 2023 Earnings Call Transcript |
Lantheus Holdings: Forget The Short Term Noise
Lantheus Seems Worth The (Very Real) Risks
Lantheus Holdings: Powerhouse Potential In 2025
PeptiDream: Opulent Dream Now A Reality
Lantheus Holdings: A Growing Business With Dominant Market Share
Lantheus' Strategic Advantage Amplified By New CMS Payment Refinements (Rating Upgrade)
Leading The Growth Of Radiopharmaceuticals: Mini Deep Dive On Lantheus
Lantheus Stock: Looking To Add After SPLASH's Belly-Flop
Lantheus: Fast-Growing Radiotherapeutics Specialist Can Benefit From Lilly's POINT Biopharma Takeover
-
What's the price of Lantheus Holdings stock today?
One share of Lantheus Holdings stock can currently be purchased for approximately $55.32.
-
When is Lantheus Holdings's next earnings date?
Unfortunately, Lantheus Holdings's (LNTH) next earnings date is currently unknown.
-
Does Lantheus Holdings pay dividends?
No, Lantheus Holdings does not pay dividends.
-
How much money does Lantheus Holdings make?
Lantheus Holdings has a market capitalization of 6.21B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 38.65% to 1.3B US dollars.
-
What is Lantheus Holdings's stock symbol?
Lantheus Holdings, Inc. is traded on the NASDAQ under the ticker symbol "LNTH".
-
What is Lantheus Holdings's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Lantheus Holdings?
Shares of Lantheus Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Lantheus Holdings's key executives?
Lantheus Holdings's management team includes the following people:
- Ms. Mary Anne Heino Chief Executive Officer, Pres & Director(age: 65, pay: $1,430,000)
- Mr. Robert J. Marshall Jr., CFA Chief Financial Officer & Treasurer(age: 58, pay: $648,620)
-
How many employees does Lantheus Holdings have?
As Jul 2024, Lantheus Holdings employs 834 workers.
-
When Lantheus Holdings went public?
Lantheus Holdings, Inc. is publicly traded company for more then 10 years since IPO on 25 Jun 2015.
-
What is Lantheus Holdings's official website?
The official website for Lantheus Holdings is lantheus.com.
-
Where are Lantheus Holdings's headquarters?
Lantheus Holdings is headquartered at 331 Treble Cove Road, North Billerica, MA.
-
How can i contact Lantheus Holdings?
Lantheus Holdings's mailing address is 331 Treble Cove Road, North Billerica, MA and company can be reached via phone at 978 671 8001.
-
What is Lantheus Holdings stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Lantheus Holdings in the last 12 months, the avarage price target is $159. The average price target represents a 187.41% change from the last price of $55.32.
Lantheus Holdings company profile:

Lantheus Holdings, Inc.
lantheus.comNASDAQ
834
Drug Manufacturers - Specialty & Generic
Healthcare
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
North Billerica, MA 01862
CIK: 0001521036
ISIN: US5165441032
CUSIP: 516544103